

1 Pneumococcal Serotype Prevalence in Southeast Asia: A Systematic Review and Meta-Analysis

2 Alex J. J. Lister MScPH<sup>1\*</sup>, Evelin Dombay PhD<sup>1</sup>, David W. Cleary PhD<sup>2,3</sup> and Stuart C. Clarke PhD<sup>1,4,5,6,7</sup>

3 <sup>1</sup> Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK

4 <sup>2</sup> Institute of Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham

5 <sup>3</sup> NIHR Birmingham Biomedical Research Centre, Institute of Translational Medicine, Birmingham

6 <sup>4</sup> NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Trust, Southampton,  
7 UK

8 <sup>5</sup> Global Health Research Institute, University of Southampton, Southampton, UK.

9 <sup>6</sup> School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.

10 <sup>7</sup> Centre for Translational Research, IMU Institute for Research, Development, and Innovation (IRDI), Kuala  
11 Lumpur, Malaysia.

12

13 \*Corresponding author: Mr Alex Lister, Faculty of Medicine, Infectious Disease Epidemiology Group,  
14 University of Southampton, Mail point 814, Level C, Sir Henry Wellcome Laboratories, South Block,  
15 University Hospital Southampton Foundation NHS Trust, Southampton SO16 6YD, UK

16 Email address: a.lister@soton.ac.uk

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32 **Abstract**

33 **Background**

34 The prevalence of *Streptococcus pneumoniae* serotypes in the ASEAN region is not well studied despite severe  
35 pneumococcal infections being a major cause of death among children in the region. This information is crucial  
36 for understanding the epidemiology of the disease and guiding vaccine policies. Our study aimed to provide a  
37 thorough analysis of the pneumococcal serotypes in ASEAN prior to vaccine introduction to assist countries in  
38 formulating evidence-based vaccine policies.

39 **Methods**

40 We conducted a systematic review and meta-analysis of studies reporting *S. pneumoniae* serotypes from carriage,  
41 invasive disease (IPD) and non-invasive disease (non-IPD) published up until 31<sup>st</sup> December 2022 using PubMed,  
42 PubMed Central, Ovid MEDLINE and Scopus databases, reference lists and search engines. Data prior to the  
43 national introduction of conjugate vaccines in the ASEAN region were included. Non-English, animal, case  
44 studies, reviews, and studies on antibiotic resistance only were excluded. The quality of studies was examined  
45 using the CASP and the JBI's Critical Appraisal Tools. The frequency of serogroups and serotypes was calculated,  
46 and vaccine coverage was estimated by the addition of vaccine serotypes as a fraction of the total number of  
47 isolates per age group. This study was registered with PROSPERO CRD42022243994.

48 **Findings**

49 A total of 940 studies were identified, and 99 and 84 relevant papers were included in the qualitative and  
50 quantitative analyses, respectively. A total of 16,396 isolates were identified, spread across all body sites and ages,  
51 with vaccine-covered serotypes 19F (n = 2,061, 12.57% [95%CI: 12.07 – 13.09]), 23F (n = 1,508, 9.20% [95%CI:  
52 8.76 – 9.65]) and 6B (n = 1,160, 7.07% [95%CI: 6.69 – 7.48]) occurring most often. Non-vaccine types *e.g.*, 6AB  
53 (n = 617, 3.76% [95%CI: 3.48 – 4.07]), 15BC (n = 35, 2.57% [95%CI: 2.33 – 2.82]) and 34 (n = 260, 1.59%  
54 [95%CI: 1.40 – 1.79]) were also frequently observed.

55 **Interpretation**

56 The most common serotypes found in IPD, non-IPD, and carriage in ASEAN are covered by currently available  
57 conjugate vaccines. This underscores the importance of vaccination and predicts future success in reducing the  
58 burden of pneumococcal disease. The data gathered offers important insights into pneumococcal serotype  
59 epidemiology across the different countries belonging to ASEAN.

60

61

62

63

64

65

## 66 Introduction

67 *Streptococcus pneumoniae* is a bacterial pathogen responsible for potentially life-threatening diseases, such as  
68 meningitis, pneumonia, and septicaemia collectively referred to as invasive pneumococcal diseases (IPD).  
69 Additionally, infections can result in less severe, non-invasive diseases (non-IPD) including sinusitis and otitis  
70 media (OM). The bacteria can be carried asymptotically in the upper respiratory tract (URT) as part of the  
71 normal microflora (1). Asymptomatic carriage can lead to pneumococcal disease if the bacteria cross the  
72 mucosal membrane and evade the host immune system (2). While the likelihood of developing pneumococcal  
73 disease from carriage is low, it can still contribute to the transmission thereby increasing the overall burden of  
74 pneumococcal disease in the population (3). Pneumococcal disease burden and mortality are the highest in low-  
75 and middle-income countries (LMICs) due to factors including poverty and malnutrition, limited access to  
76 healthcare, high prevalence of antibiotic resistant pneumococci and lower vaccination rates and/or coverage (4,  
77 5). Without improvements in the latter, the burden of pneumococcal disease remains high.

78 Pneumococcal vaccines have been developed by leveraging the immunogenicity of the pneumococcal capsule,  
79 which defines over 100 different serotypes currently recognised (6). The differences in the polysaccharide  
80 composition of the capsule allows for serotype-specific protection through vaccination. There are currently two  
81 types of pneumococcal vaccines available. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is  
82 effective against 23 serotypes and is recommended for all adults aged 65 years and older. Age-specific  
83 vaccination with PPV23 is necessary because polysaccharides lack T-cell stimulating activity, which makes it  
84 difficult to generate an effective immune response in children and antibody-deficient adults (7). The other  
85 formulation, polysaccharide conjugate vaccines (PCVs), such as Synflorix® (PCV10, GlaxoSmithKline) and  
86 Prevnar 13® (PCV13, Pfizer), contain semi-purified capsular polysaccharides from 10 and 13 pneumococcal  
87 serotypes, respectively, covalently linked to a protein carrier. These protein carriers elicit a T-cell-dependent  
88 immune response, making conjugate vaccines more effective in children (8, 9). The first pneumococcal  
89 conjugate vaccine, PCV7 is no longer in use. The serotypes covered by PCV10 are 1, 4, 5, 6B, 7F, 9V, 14, 18C,  
90 19F, and 23F. This vaccine is licensed for use in infants and children from 6 weeks up to 5 years of age (10). A  
91 higher valency PCV, the 13-valent vaccine covers the same serotypes as PCV10, with the extension to serotypes  
92 3, 6A and 19A (11). PCV13 and the newer PCV15 are currently recommended by the World Health  
93 Organization (WHO) for use in all countries that have not yet introduced pneumococcal conjugate vaccines into  
94 their routine immunization programs (12). PCV15 (Vaxneuvance, Merck), has been approved for use as of June  
95 2022 and is being licensed throughout the European Union since 2021. It contains the same serotypes as PCV13  
96 plus serotypes 22F and 33F (13) and it is currently recommended for persons aged <19 years (14, 15). Higher  
97 valent vaccines are entering the market, with the twenty-serotype vaccine (PCV20, Apexxnar R, Pfizer) being  
98 approved for use in the >18 years of age population by the European Medicines Agency and the Food and Drug  
99 Administration (13, 16 – 19). This vaccine contains the serotypes found in PCV15, with the addition of  
100 serotypes 8, 10A, 11A, 12F, and 15B and is recommended to countries that have already implemented PCV to  
101 prevent the emergence of non-vaccine types (NVTs).

102 Between 2010 and 2019, it is estimated that PCV13 vaccination prevented 175.2 million cases of pneumococcal  
103 diseases and 624,904 deaths worldwide (20). According to the World Health Organization (WHO), as of 2021,  
104 more than 150 countries have introduced pneumococcal conjugate vaccines into their routine immunization

105 programs. However, the extent of implementation varies. Some countries have PCVs as part of their routine  
106 immunization schedule, while others use it on an *ad hoc* basis where individuals are given a choice to purchase  
107 the vaccine. Unfortunately, certain low- and middle-income countries (LMICs) are unable to adopt vaccination  
108 due to financial constraints and vaccine policies needing review. The paucity of country-specific data on disease  
109 burden and the cost of pneumococcal conjugate vaccines (PCVs) are among the primary reasons for the slow  
110 adoption of PCVs in LMICs (21).

111 Ten nations in the South-East Asian region form the Association of Southeast Asian Nations (ASEAN) and are  
112 amongst those with the highest burden of childhood pneumonia globally. The incidence of pneumonia in  
113 children in Southeast Asia is 2,500 cases per 100,000 children which is higher than the global average of 1,400  
114 cases per 100,000 children according to data by the UNICEF (22). The disparity in vaccine availability  
115 discussed above is seen in Southeast Asian countries. In Thailand, PCV13 was first introduced in 2011, not  
116 currently as part of the routine immunization programme but it can be purchased at private clinics and hospitals  
117 (23). In Malaysia, PCVs were similarly available from around 2005 through private healthcare facilities.  
118 However, in 2020 Malaysia took the next step and included PCV10 in their NIPs. Other Southeast Asian  
119 countries that have introduced PCV in their NIPs are Cambodia, the Philippines, Myanmar and Laos, and there  
120 has been partial introduction in Indonesia. Vaccines are given to certain risk groups in Brunei, and Vietnam is  
121 yet to introduce a PCV.

122 The primary objective of this study was to quantify the importance of PCV vaccine implementation and/or  
123 amendment in the remainder of ASEAN countries by providing a comprehensive review of the prevalence of  
124 pneumococcal serotypes across the region and an update on the 2012 review in the region (24). Using a  
125 systematic approach, this study aims to estimate the vaccine coverage in countries where PCV has been  
126 implemented and in those where the vaccine is yet to be introduced. With the evidence gathered in this study,  
127 we aim to inform policy makers about the importance of pneumococcal vaccination in reducing the burden and  
128 mortality of pneumococcal diseases so that further considerations can be made on an improved vaccine policy.

129

## 130 **Methods**

131 Online databases PubMed, PubMed Central, Ovid MEDLINE and Scopus were systematically searched for  
132 literature regarding the serotype prevalence of *S. pneumoniae* across the Southeast Asian countries belonging to  
133 ASEAN. No lower date limit was set and included papers published up until the 31<sup>st</sup> December 2022. Search  
134 terms included: 'Brunei', 'Cambodia', 'Indonesia', 'Malaysia', 'Myanmar', 'Laos', 'Philippines', 'Singapore',  
135 'Thailand', 'Timor', 'Vietnam', 'SE Asia\*', 'South East Asia\*', 'Southeast Asia\*', 'Southeastern Asia\*',  
136 'Streptococcus pneumoniae', 'S pneumoniae', 'pneumococc\*', 'pneumonia', 'serotype\*', 'serogroup\*',  
137 'seroprevalence', separated by the binary operators 'OR' and 'AND'. Asterisks represent a truncation of the  
138 term.

139 Inclusion criteria included full texts that reported *S. pneumoniae* serotypes in countries that belonged to  
140 ASEAN, those which reported both invasive, non-invasive disease data with the inclusion of carriage studies  
141 regardless of age or gender reported. Both serogroup and serotype data were included. Exclusion criteria of  
142 studies included those that were not written in English, animal studies, case studies, reviews, studies that only

143 reported strains with antibiotic resistance, studies of single serotypes, articles on biochemical techniques or  
144 genetics for serotyping, non-ASEAN studies, and studies which only reported infection numbers or antibody  
145 levels without reporting serotypes. From the initial search, returned papers were scanned for duplicates, which  
146 were then removed. Titles and abstracts were analysed, and any papers deemed not relevant were removed.  
147 Remaining papers' full texts were then reviewed by two researchers, using the criteria for inclusion/exclusion in  
148 the qualitative analysis. Studies that then met inclusion criteria for quantitative analysis were then reviewed and  
149 serotype data was extracted. Exclusion criteria for quantitative analysis included studies that were conducted  
150 after the respective countries' date of PCV implementation and those studies that overlapped with others already  
151 included.

152 The assessment of articles from a quality perspective was undertaken using a by using a consolidation of two  
153 checklist-style quality assessment frameworks: The Critical Appraisal Skills Programme (CASP) checklists and  
154 the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies (25, 26).

155 Country data was grouped into source type categories (IPD, non-IPD and carriage). IPD isolates were defined as  
156 samples taken from a normally sterile site such as blood or cerebrospinal fluid (CSF), non-IPD isolates were  
157 defined as those taken from a non-sterile site and experienced non-invasive disease such as bronchitis, otitis  
158 media and other mild pneumococcal infection. Carriage isolates were defined as those taken from patients  
159 experiencing neither IPD nor non-IPD, including generally healthy populations. Serotypes and groups were  
160 classed as vaccine type (VT) serotypes, which were those serotypes found in the PCVs. Non-vaccine types  
161 (NVT), unencapsulated non-typeable (NT) serotypes and unknown (N/A) serotypes formed a separate category.  
162 Unknown serotypes were classed as those that could not be determined through methodologies or from studies  
163 which do not explicitly state the specific serotype. Some studies reported serotypes that were either VTs or  
164 NVTs but remained unidentified, so were grouped into additional 'PCV related unknown' and 'non-PCV related  
165 unknown' serotypes. Serotype prevalence was stratified by age categories including 'under-five years', 'over  
166 five years' and 'unreported', the latter used for studies that did not specify the age of the participant or did not  
167 fit the over and under five classifications, such as data that spanned the age ranges without further details.

168 GraphPad Prism 9 (GraphPad Software, Inc.) was used for data management and graph construction. Numbers  
169 of isolates were grouped into their respective serotypes under each country, as well as by age category.  
170 Percentage coverage of the vaccines was calculated by the addition of vaccine serotypes as a fraction of the total  
171 number of isolates per age group. Percentages were expressed with 95% confidence intervals (95% CI) in tabular  
172 and boxplot format. GraphPad Prism 9 was used for graph construction and to perform the statistical analysis.

173 The funder of the study had no role in the study design, data collection, data analysis, data interpretation or  
174 writing of the report.

175

176

177

178

179 **Results**

180 In total, 940 articles were identified. The initial database search resulted in n = 934 articles (PubMed = 396,  
181 Ovid Medline = 153, Scopus = 294, PMC = 91) with the remaining six identified from search engine keywords.  
182 From this collection, n = 452 studies were duplicates. Screening abstracts and titles resulted in n = 389 records  
183 being excluded. From the identified articles, n = 99 met the inclusion criteria for qualitative analysis (Table 1)  
184 and of these, n = 84 were included in the quantitative analysis (Figure 1).

185 It was decided that the study on the Thailand / Myanmar border (27) would be added to the Myanmar data as,  
186 despite residing in a refugee camp in Thailand at time of study, the population were originally refugees from  
187 Myanmar. The results from all studies were broken down by country.

188

189  Figure 1. PRISMA Statement showing search and study selection.

190 Table 1. Qualitative analysis of studies investigating pneumococcal serotype prevalence in ASEAN countries

191

192 \*Study omitted to avoid risk of duplication. \*\*Study omitted due to serotype data that could not be determined from the manuscript. \*\*\*Study omitted due to serotypes  
193 coming from post-PCV in population. \*\*\*\*Study omitted due to no full text

194 **All Countries**

195 A total of n = 16,396 isolates were identified with n = 4,129 (25.18% [95%CI: 24.52 – 25.85]) from IPD, n =  
196 1,752 isolates (10.69%, [95%CI:10.22 – 11.17]) from non-IPD, and n = 10,053 isolates from carriage (61.31%,  
197 [95%CI: 60.56 – 62.06]) (Table 2). The remaining n = 462 (2.82%, [95%CI: 2.57 – 3.08]) were from unknown  
198 sources. The most common vaccine types across all sources were 19F (n = 2,061, 12.57% [95%CI: 12.07 –  
199 13.09]), followed by 23F (n = 1,508, 9.20% [95%CI: 8.76 – 9.65]) and 6B (n = 1,160, 7.07% [95%CI: 6.69 –  
200 7.48]) (Table 2). The three most common NVTs were 6AB (n = 617, 3.76% [95%CI: 3.48 – 4.07]), 15BC (n =  
201 35, 2.57% [95%CI: 2.33 – 2.82]) and 34 (n = 260, 1.59% [95%CI: 1.40 – 1.79]). PCV10 and PCV13, PCV15  
202 and PCV20 serotypes accounted for 40.06% [95%CI: 39.31 – 40.81], 49.93% [95%CI: 49.16 – 50.70], 50.22%  
203 [95%CI: 49.45 – 50.99] and 51.95% [95%CI: 51.18 – 52.71] respectively. Non-typeable isolates totalled n =  
204 1,708 (10.42%, [95%CI: 9.95 – 10.89]) and unknown serotypes, including those that were reported as  
205 autoagglutinated, totalled n = 2,350 (14.33% [95%CI: 13.80 – 14.88]) of total isolates. Fig2, Fig 3, Fig4 and  
206 Fig5 show the split of serotype counts from across IPD, non-IPD, carriage and unknown sources.

207 Table 2. Serotype counts and percentages for all countries in ASEAN, split by age category and invasive, non-  
208 invasive, carriage sources and from sources which could not be determined.

209 Fig2. Serotypes from across ASEAN invasive disease studies. (A) Number of isolates for each respective  
210 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
211 studies on IPD. (B) Frequency of isolates for each respective serotype found in PCV10, 13, 15 and 20, including  
212 number of NVTs and unknown serotypes from identified studies.

213 Fig3. Serotypes from across ASEAN non-invasive disease studies. (A) Number of isolates for each respective  
214 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
215 studies on non-IPD. (B) Frequency of isolates for each respective serotype found in PCV10, 13, 15 and 20,  
216 including number of NVTs and unknown serotypes from identified studies.

217 Fig4. Serotypes from across ASEAN carriage studies. (A) Number of isolates for each respective serotype found  
218 in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies on  
219 carriage. (B) Frequency of isolates for each respective serotype found in PCV10, 13, 15 and 20, including  
220 number of NVTs and unknown serotypes from identified studies.

221 Fig5. Serotypes from across ASEAN studies where source could not be determined. (A) Number of isolates for  
222 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
223 from identified studies for which source could not be identified. (B) Frequency of isolates for each respective  
224 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
225 studies.

226 **Serogroup and serotype prevalence among disease and carriage across ASEAN**

227 The frequency of serogroups and individual serotypes has been calculated for IPD, non-IPD and carriage,  
228 separately. The three most common serogroups in all types of conditions were found to be consistently 6, 19 and  
229 23 (Table 3). The rank order of serotypes was found to be not as consistent; serotypes 1 (39.87%), 3 (28.39%),  
230 and 4 (21.09%) were identified as the most prevalent in causing IPDs, while serotypes 3 (34.51%), 34 (25.35%),



231 and 1 (23.24%) were commonly observed in non-IPDs. On the other hand, serotypes 34 (53.65%), 3 (21.35%),  
232 and 4 (7.29%) were frequently found in carriage (Table 4).

233 Table 3. Rank order of serogroups across IPD, non-IPD and carriage sources in ASEAN

234 Table 4. Rank order of serotypes across IPD, non-IPD and carriage sources in ASEAN

235 **Brunei**

236 No studies were identified for Brunei.

237 **Cambodia**

238 A total of n = 1,153 isolates were identified with n = 270 (23.42% [95%CI: 21.00 – 25.97]) from IPD, n = 140  
239 isolates (12.14%, [95%CI: 10.31 – 14.17]) from non-IPD and n = 743 isolates from carriage (64.44%, [95%CI:  
240 61.60 – 67.21]). The most common vaccine types across all sources were 19F (n = 143, 12.4% [95%CI: 10.55 –  
241 14.44]), followed by 23F (n = 108, 9.37% [95%CI: 7.75 – 11.20]) and 6B (n = 106, 9.19% [95%CI: 7.59 –  
242 11.01]) (Table 5). The three most common NVTs were 6AB (n = 96, 8.33% [95%CI: 6.80 – 10.07]), 34 (n = 35,  
243 3.04% [95%CI: 2.12 – 4.20]) and 35C (n = 19, 1.65% [95%CI: 0.99 – 2.56]). PCV10 and PCV13, PCV15 and  
244 PCV20 serotypes accounted for 41.28% [95%CI: 38.42 – 44.19], 58.20% [95%CI: 55.29 – 61.06], 58.37%  
245 [95%CI: 55.46 – 61.23] and 64.44% [95%CI: 61.60 – 67.21] of all isolates respectively. Non-typeables  
246 accounted for n = 88 (7.63%, [95%CI: 6.17 – 9.32]). No unknown serotypes were reported. Fig6, Fig7, Fig8  
247 show the split of serotype counts from across IPD, non-IPD and carriage sources.

248 Table 5. Serotype counts and percentages for all countries in Cambodia, split by age category and invasive, non-  
249 invasive and carriage sources.

250 Fig6. Serotypes from across Cambodian invasive disease studies. (A) Number of isolates for each respective  
251 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
252 studies for which source could not be identified for Cambodia invasive disease. (B) Frequency of isolates for  
253 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
254 from identified studies.

255 Fig7. Serotypes from across Cambodian non-invasive disease studies. (A) Number of isolates for each  
256 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
257 identified studies for which source could not be identified for Cambodia non-invasive disease. (B) Frequency of  
258 isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown  
259 serotypes from identified studies.

260

261 Fig8. Serotypes from across Cambodian carriage studies. (A) Number of isolates for each respective serotype  
262 found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for  
263 which source could not be identified for Cambodia carriage. (B) Frequency of isolates for each respective  
264 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
265 studies.

266

267

268 **Indonesia**

269 A total of n = 2,012 isolates were identified. N = 4 (0.20% [95%CI: 0.05 – 0.51]) were from IPD, n = 65 isolates  
270 (3.23%, [95%CI: 2.50 – 4.10]) from non-IPD and n = 1,943 isolates from carriage (96.57%, [95%CI: 95.68 –  
271 97.32]). The most common vaccine types across all sources were 19F (n = 175, 8.70% [95%CI: 7.50 – 10.01]),  
272 followed by 23F (n = 144, 7.16% [95%CI: 6.07 – 8.37]) and 14 (n = 76, 3.78% [95%CI: 2.99 – 4.71]) (Table 6).  
273 The three most common NVTs were 6AB (n = 259, 12.87% [95%CI: 11.44 – 14.42]), 15BC (n = 134, 6.66%  
274 [95%CI: 5.61 – 7.84]) and 23A (n = 81, 4.03% [95%CI: 3.21 – 4.98]). PCV10 and PCV13, PCV15 and PCV20  
275 serotypes accounted for 24.45% [95%CI: 22.59 – 26.39], 34.59% [95%CI: 32.51 – 36.72], 35.19% [95%CI:  
276 33.10 – 37.32] and 38.97% [95%CI: 36.83 – 41.14] of all isolates respectively. Non-typeables accounted for n =  
277 312 (15.51%, [95%CI: 13.95 – 17.16]) and unknown serotypes accounted for n = 24 (1.19%, [95%CI: 0.77 –  
278 1.77]) of total isolates. Fig9, Fig10, Fig11 show the split of serotype counts from across IPD, non-IPD and  
279 carriage sources.

280 Table 6. Serotype counts and percentages for all countries in Indonesia, split by age category and invasive, non-  
281 invasive and carriage sources.

282 Fig9. Serotypes from across Indonesian invasive disease studies. (A) Number of isolates for each respective  
283 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
284 studies for which source could not be identified for Indonesia invasive disease. (B) Frequency of isolates for  
285 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
286 from identified studies.

287 Fig10. Serotypes from across Indonesian non-invasive disease studies. (A) Number of isolates for each  
288 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
289 identified studies for which source could not be identified for Indonesia non-invasive disease. (B) Frequency of  
290 isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown  
291 serotypes from identified studies.

292 Fig11. Serotypes from across Indonesian carriage studies. (A) Number of isolates for each respective serotype  
293 found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for  
294 which source could not be identified for Indonesia carriage. (B) Frequency of isolates for each respective  
295 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
296 studies.

297

298 **Laos**

299 A total of n = 217 isolates were identified. N = 33 (15.21%, [95%CI: 10.71 – 20.69]), n = 0 from non-IPD and n  
300 = 184 isolates from carriage (84.79%, [95%CI: 79.31 – 89.29]). The most common vaccine types across all  
301 sources were 6B (n =49, 22.58% [95%CI: 17/20 – 28.73]), followed by 23F (n = 37, 17.05% [95%CI: 12.30 -

22.73]) and 19F (n = 34, 15.67% [95%CI: 11.10 – 21.20]) (Table 7). The three most common NVTs were 15BC (n = 6, 2.76%, [95%CI: 1.02 – 5.92]), 6ABC (n = 3, 1.38% [95%CI: 0.29 – 3.99]), with the remaining serotypes 15C, 23B and 38 each having n = 1 (0.46%, [95%CI: 0.01 – 2.54]) each. PCV10, PCV13, PCV15 and PCV20 serotypes accounted for 63.59% [95%CI: 56.81 – 70.00], 69.12% [95%CI: 62.52 – 75.20], 69.12% [95%CI: 62.52 – 75.20] and 69.12% [95%CI: 62.52 – 75.20] of all isolates respectively. Non-typeables accounted for n = 55 (25.35%, [95%CI: 19.70 – 31.68]) and unknown serotypes accounted for zero of total isolates. Fig12, Fig13, Fig14 show the split of serotype counts from across IPD, non-IPD and carriage sources.

Table 7. Serotype counts and percentages for all countries in Laos, split by age category and invasive, non-invasive and carriage sources.

Fig12. Serotypes from across Laos invasive disease studies. (A) Number of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for which source could not be identified for Laos invasive disease. (B) Frequency of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies.

Fig13. Serotypes from across Laos non-invasive disease studies. (A) Number of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for which source could not be identified for Laos non-invasive disease. (B) Frequency of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies. As seen, no serotypes were identified.

Fig14. Serotypes from across Laos carriage studies (A) Number of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for which source could not be identified for Laos carriage. (B) Frequency of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies.

## Malaysia

A total of n = 2,210 isolates were identified. N = 883 (39.95% [95%CI: 37.90 – 42.03]) were from IPD, n = 778 isolates (35.20%, [95%CI: 33.31 – 37.24]) from non-IPD, n = 426 isolates from carriage (19.28%, [95%CI: 17.65 – 20.98]) and n = 123 (5.57% [95%CI: 4.65 – 6.60]) were from unknown source. The most common vaccine types across all sources were 19F (n = 335, 15.16% [95%CI: 13.69 – 16.72]), followed by 14 (n = 184, 8.33% [95%CI: 7.21 – 9.56]) and 23F (n = 172, 7.78% [95%CI: 6.70 – 8.98]) (Table 8). The three most common NVTs were 6AB (n = 87, 3.94%, [95%CI: 3.16 – 4.83]), 23A (n = 37, 1.67% [95%CI: 1.18 – 2.30]) and 6C (n = 26, 1.18% [95%CI: 0.77 – 1.72]). PCV10 and PCV13, PCV15 and PCV20 serotypes accounted for 47.01% [95%CI: 44.91 – 49.12], 62.40% [95%CI: 60.34 – 64.42], 62.94% [95%CI: 60.89 – 64.96] and 65.16% [95%CI: 63.13 – 67.15] of all isolates respectively. Non-typeables accounted for n = 154 (6.97%, [95%CI: 5.94 – 8.11]) of all isolates and unknown serotypes accounted for n = 34 (1.54% [95%CI: 1.07 – 2.14]) of total isolates. Fig15, Fig16, Fig17, Fig18 show the split of serotype counts from across IPD, non-IPD, carriage and unknown sources.

339 Table 8. Serotype counts and percentages for all countries in Malaysia, split by age category and invasive, non-  
340 invasive, carriage sources and from sources which could not be determined.

341 Fig15. Serotypes from across Malaysian invasive disease studies. (A) Number of isolates for each respective  
342 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
343 studies for which source could not be identified for Malaysia invasive disease. (B) Frequency of isolates for  
344 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
345 from identified studies.

346 Fig16. Serotypes from across Malaysian non-invasive disease studies. (A) Number of isolates for each  
347 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
348 identified studies for which source could not be identified for Malaysia non-invasive disease. (B) Frequency of  
349 isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown  
350 serotypes from identified studies.

351 Fig17. Serotypes from across Malaysian carriage studies (A) Number of isolates for each respective serotype  
352 found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for  
353 which source could not be identified for Malaysia carriage. (B) Frequency of isolates for each respective  
354 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
355 studies.

356 Fig18. Serotypes from across Malaysian studies where source could not be determined. (A) Number of isolates  
357 for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
358 from identified studies for which source could not be identified for Malaysia unknown sources. (B) Frequency  
359 of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and  
360 unknown serotypes from identified studies.

361

## 362 Myanmar

363 A total of n = 4,420 isolates were identified. Zero isolates were from IPD, n = 24 isolates (0.54%, [95%CI: 0.35  
364 – 0.81]) from non-IPD and n = 4,396 isolates from carriage (99.46%, [95%CI: 99.19 – 99.65]). The most  
365 common vaccine types across all sources were 19F (n = 606, 13.71% [95%CI: 12.71 – 14.76]), followed by 23F  
366 (n = 473, 10.70% [95%CI: 9.80 – 11.65]) and 6B (n = 337, 7.62% [95%CI: 6.86 – 8.45]) (Table 9). The three  
367 most common NVTs were 15BC (n = 171, 3.87% [95%CI: 3.32 – 4.48]), 34 (n = 139, 3.14% [95%CI: 2.65 –  
368 3.70]), 6C (n = 117, 2.65% [95%CI: 2.19 – 3.16]). PCV10, PCV13, PCV15 and PCV20 serotypes accounted for  
369 36.92% [95%CI: 35.50 – 38.37], 43.67% [95%CI: 42.20 – 45.14], 43.67% [95%CI: 42.20 – 45.14] and 43.67%  
370 [95%CI: 42.20 – 45.14] of all isolates respectively. Non-typeables accounted for n = 665 (15.05% [95%CI:  
371 14.00 – 16.13]) of total isolates and unknown serotypes accounted for n = 1148, 25.97% [95%CI: 24.69 – 27.29]  
372 of total isolates. Fig19, Fig20, Fig21 show the split of serotype counts from across IPD, non-IPD and carriage  
373 sources.

374 Table 9. Serotype counts and percentages for all countries in Myanmar, split by age category and invasive, non-  
375 invasive and carriage sources.

376

377 Fig19. Serotypes from across Myanmar invasive disease studies. (A) Number of isolates for each respective  
378 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
379 studies for which source could not be identified for Myanmar invasive disease. (B) Frequency of isolates for  
380 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
381 from identified studies.

382

383 Fig20. Serotypes from across Myanmar non-invasive disease studies. (A) Number of isolates for each respective  
384 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
385 studies for which source could not be identified for Myanmar non-invasive disease (B) Frequency of isolates for  
386 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
387 from identified studies.

388 Fig21. Serotypes from across Myanmar carriage studies. (A) Number of isolates for each respective serotype  
389 found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for  
390 which source could not be identified for Myanmar carriage (B) Frequency of isolates for each respective  
391 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
392 studies.

393

### 394 **Philippines**

395 A total of n = 587 isolates were identified. N = 365 (62.18% [95%CI: 58.12 – 66.12]) were from IPD, n = 51  
396 isolates (8.69%, [95%CI: 6.54 – 11.27]) from non-IPD, n = 158 isolates from carriage (26.92%, [95%CI: 23.37–  
397 30.70]) and n = 13 (2.10%, [95%CI: 1.18 – 3.76]) were of unknown source. The most common vaccine types  
398 across all sources were 1 (n = 57, 9.71% [95%CI: 7.44 – 12.40]), followed by 5 (n = 34, 5.79% [95%CI: 4.04 –  
399 8.00]) and 14 (n = 29, 4.94% [95%CI: 3.33 – 7.02]) (Table 10). The three most common NVTs were 6 (n= 43,  
400 7.33% [95%CI: 5.35 – 9.74]), 23 (n = 23, 3.92% [95%CI: 2.50– 5.82]) and 18 (n = 15, 2.56% [95%CI: 1.44 –  
401 4.18]). PCV10, PCV13, PCV15 and PCV20 serotypes accounted for 32.54% [95%CI: 28.76 – 36.49], 39.52%  
402 [95%CI: 35.54 – 43.61], 39.52% [95%CI: 35.54 – 43.61] and 40.55% [95%CI: 36.54 – 44.64] of all isolates  
403 respectively. Non-typeables accounted for n = 38 (6.47% [95%CI: 4.62 – 8.78]) and unknown serotypes  
404 accounted for n = 84 (14.31% [95%CI: 11.58 – 17.41]) of total isolates. Fig22, Fig23, Fig24, Fig25 show the  
405 split of serotype counts from across IPD, non-IPD, carriage and unknown sources.

406 Table 10. Serotype counts and percentages for all countries in Philippines, split by age category and invasive,  
407 non-invasive, carriage sources and from sources which could not be determined.

408 Fig22. Serotypes from across Philippines invasive disease studies. (A) Number of isolates for each respective  
409 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
410 studies for which source could not be identified for Philippines invasive disease. (B) Frequency of isolates for

411 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
412 from identified studies.

413 Fig23. Serotypes from across Philippines non-invasive disease studies. (A) Number of isolates for each  
414 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
415 identified studies for which source could not be identified for Philippines non-invasive disease. (B) Frequency  
416 of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and  
417 unknown serotypes from identified studies.

418 Fig24. Serotypes from across Philippines carriage disease studies. (A) Number of isolates for each respective  
419 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
420 studies for which source could not be identified for Philippines carriage. (B) Frequency of isolates for each  
421 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
422 identified studies.

423 Fig25. Serotypes from across Philippines studies where source could not be determined. (A) Number of isolates  
424 for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
425 from identified studies for which source could not be identified for Philippines unknown sources. (B) Frequency  
426 of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and  
427 unknown serotypes from identified studies.

428

## 429 Singapore

430 A total of  $n = 552$  isolates were identified.  $N = 331$  (59.96% [95%CI: 55.74 – 64.08]) were from IPD, zero were  
431 from non-IPD,  $n = 41$  isolates from carriage (7.43%, [95%CI: 5.38 – 9.94]) and  $n = 180$  (32.61%, [95%CI:  
432 28.71 – 36.70]) were from unknown source. The most common vaccine types across all sources [Figure 9] were  
433 19F ( $n = 96$ , 17.39% [95%CI: 14.32 - 20.82]), followed by 14 ( $n = 91$ , 16.49% [95%CI: 13.49 – 19.85]) and 23F  
434 ( $n = 74$ , 13.41% [95%CI: 10.67 – 16.54]) (Table 11). The three most common NVTs were 6 ( $n = 24$ , 4.35%  
435 [95%CI: 2.81 – 6.40]), 19 ( $n = 19$ , 3.44% [95%CI: 2.08 – 5.32]) and 20 ( $n = 10$ , 1.81% [95%CI: 0.87 – 3.31]).  
436 PCV10 and PCV13, PCV15 and PCV20 serotypes accounted for 60.51% [95%CI: 56.29 – 64.61], 69.20%  
437 [95%CI: 65.17 – 73.03], 70.83% [95%CI: 66.85 – 74.60] and 74.64% [95%CI: 70.79 – 78.22] of all isolates  
438 respectively. Non-typeables accounted for  $n = 12$  (2.17%, [95%CI: 1.13 – 3.77]) and unknown serotypes  
439 accounted for  $n = 27$  (4.89% [95%CI: 3.25 – 7.04]) of total isolates. Fig26, Fig27, Fig28, Fig29 show the split  
440 of serotype counts from across IPD, non-IPD, carriage and unknown sources.

441 Table 11. Serotype counts and percentages for all countries in Singapore, split by age category and invasive,  
442 non-invasive, carriage sources and from sources which could not be determined.

443 Fig26. Serotypes from across Singapore invasive disease studies. (A) Number of isolates for each respective  
444 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
445 studies for which source could not be identified for Singapore invasive disease. (B) Frequency of isolates for  
446 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
447 from identified studies.

448

449 Fig27. Serotypes from across Singapore non-invasive disease studies. (A) Number of isolates for each  
450 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
451 identified studies for which source could not be identified for Singapore non-invasive disease. (B) Frequency of  
452 isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown  
453 serotypes from identified studies.

454

455 Fig28. Serotypes from across Singapore carriage studies. (A) Number of isolates for each respective serotype  
456 found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for  
457 which source could not be identified for Singapore carriage. (B) Frequency of isolates for each respective  
458 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
459 studies.

460 Fig29. Serotypes from across Singapore studies where source could not be determined. (A) Number of isolates  
461 for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
462 from identified studies for which source could not be identified for Singapore unknown sources. (B) Frequency  
463 of isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and  
464 unknown serotypes from identified studies.

465

#### 466 **Timor-Leste**

467 No studies were identified for Timor-Leste.

#### 468 **Thailand**

469 A total of n = 3,016 isolates were identified. N = 1,887 (62.57% [95%CI: 60.81 – 64.30]) were from IPD, n =  
470 202 isolates (6.70%, [95%CI: 5.83 – 7.65]) from non-IPD, n = 781 isolates from carriage (25.90%, [95%CI:  
471 24.34 – 27.50]) and n = 146 (4.84%, [95%CI: 4.10 – 5.67]) were of unknown source. The most common vaccine  
472 types across all sources were 6B (n = 343, 11.37% [95%CI: 10.26 – 12.56]), followed by 23F (n = 263, 8.72%  
473 [95%CI: 7.74 – 9.78]) and 19F (n = 214, 7.10% [95%CI: 6.20 – 8.07]) (Table 12). The three most common  
474 NVTs were 6 (n = 147, 4.87%, [95%CI: 4.13 – 5.70]), 23 (n = 101, 3.35% [95%CI: 2.74 – 4.05]) and 19 (n =  
475 64, 2.12%, [95%CI: 1.64 – 2.70]). PCV10 and PCV13, PCV15 and PCV20 serotypes accounted for 44.03%  
476 [95%CI: 42.25 – 45.82], 54.44% [95%CI: 52.65 – 56.23], 54.81% [95%CI: 53.01 – 56.59] and 55.97% [95%CI:  
477 54.18 – 57.75] of all isolates respectively. Non-typeables accounted for n = 164 (5.44%, [95%CI: 4.66 – 6.31])  
478 and unknown serotypes accounted for n = 574 (19.03% [95%CI: 17.64 – 20.48]) of total isolates. Fig30, Fig31,  
479 Fig32, Fig33 show the split of serotype counts from across IPD, non-IPD, carriage and unknown sources.

480 Table 12. Serotype counts and percentages for all countries in Thailand, split by age category and invasive, non-  
481 invasive, carriage sources and from sources which could not be determined.

482

483 Fig30. Serotypes from across Thailand invasive disease studies. (A) Number of isolates for each respective  
484 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
485 studies for which source could not be identified for Thailand invasive disease. (B) Frequency of isolates for each  
486 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
487 identified studies.

488 Fig31. Serotypes from across Thailand non-invasive disease studies. (A) Number of isolates for each respective  
489 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
490 studies for which source could not be identified for Thailand non-invasive disease. (B) Frequency of isolates for  
491 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
492 from identified studies.

493 Fig32. Serotypes from across Thailand carriage studies. (A) Number of isolates for each respective serotype  
494 found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for  
495 which source could not be identified for Thailand carriage. (B) Frequency of isolates for each respective  
496 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
497 studies.

498 Fig33. Serotypes from across Thailand studies where source could not be determined. (A) Number of isolates  
499 for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
500 from identified studies for which source could not be identified for Thailand unknown source. (B) Frequency of  
501 isolates for each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown  
502 serotypes from identified studies.

503

#### 504 **Vietnam**

505 A total of n = 2,229 isolates were identified. N = 356 (15.97% [95%CI: 14.47 – 17.56]) were from IPD, n = 492  
506 isolates (22.07%, [95%CI: 20.37 – 23.85]) from non-IPD and n = 1,381 isolates from carriage (61.96%,  
507 [95%CI: 59.90 – 63.98]). The most common vaccine types across all sources were 19F (n = 469, 21.04%  
508 [95%CI: 19.37 – 22.79]), followed by 23F (n = 264, 11.84% [95%CI: 10.53 – 13.26]) and 14 (n = 191, 8.57%  
509 [95%CI: 7.44 – 9.81]) (Table 13). The three most common NVTs were 6AB (n = 174, 7.81%, [95%CI: 6.73 –  
510 9.00]), 19 (n = 104, 4.67% [95%CI: 3.83 – 5.63]) and 23 (n = 77, 3.45% [95%CI: 2.74 – 4.30]). PCV10 and  
511 PCV13, PCV15 and PCV20 serotypes accounted for 47.33% [95%CI: 45.24 – 49.43], 54.60% [95%CI: 52.50 –  
512 56.68], 54.64% [95%CI: 52.55 – 56.73] and 55.81% [95%CI: 53.72 – 57.88] of all isolates respectively. Non-  
513 typeables accounted for n = 202 (9.06%, [95%CI: 7.90 – 10.33]) and unknown serotypes accounted for n = 79  
514 (3.54% [95%CI: 2.82 – 4.40]) of total isolates. Fig34, Fig35, Fig36 show the split of serotype counts from  
515 across IPD, non-IPD and carriage sources.

516 Table 13. Serotype counts and percentages for all countries in Vietnam, split by age category and invasive, non-  
517 invasive and carriage sources.

518



519 Fig34. Serotypes from across Vietnam invasive disease studies. (A) Number of isolates for each respective  
520 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
521 studies for which source could not be identified for Vietnam invasive disease. (B) Frequency of isolates for each  
522 respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from  
523 identified studies.

524 Fig35. Serotypes from across Vietnam non-invasive disease studies. (A) Number of isolates for each respective  
525 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
526 studies for which source could not be identified for Vietnam non-invasive disease. (B) Frequency of isolates for  
527 each respective serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes  
528 from identified studies.

529 Fig36. Serotypes from across Vietnam carriage studies. (A) Number of isolates for each respective serotype  
530 found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified studies for  
531 which source could not be identified for Vietnam carriage. (B) Frequency of isolates for each respective  
532 serotype found in PCV10, 13, 15 and 20, including number of NVTs and unknown serotypes from identified  
533 studies.

534 Percentage coverage represents the minimum coverage of each vaccine, as 'unknown' variables are included in  
535 the calculation, classed as serotypes not covered by vaccines. Vaccine coverage of serotypes are for all disease  
536 types, split by age category in each country. Coverage is calculated as the percentage of VT's out of the total  
537 number of isolates, across PCV10, PCV13, PCV15 and PCV20, shown in Fig37.

538 Fig37. Forest plot of vaccine coverage for each of the currently licensed conjugates in each of the countries  
539 belonging to ASEAN. The plot shows the calculated coverage of conjugate-covered serotypes against the total  
540 number of serotypes identified in the studies.

541

542 PCV coverage over the three age categories and across pooled ASEAN data shows the lowest theoretical  
543 coverage, as unknown serotypes were also included in the calculation, under non-vaccine type numbers.

544

545

546

547

548

549

550

551

552

553 **Discussion**

554 Despite high mortality in the ASEAN region associated with childhood pneumonia, pneumococcal serotype  
555 prevalence was incompletely understood. This study fills an important knowledge gap that has not been  
556 addressed since 2012.<sup>24</sup> Over the last ten years the vaccination landscape has changed due to the introduction of  
557 the PCV13, as well as the development of other vaccines with higher valency. Additionally, some countries  
558 have since successfully implemented PCVs into their NIPs, while others have yet to do so. Serotype  
559 replacement in disease, the development of new vaccines and the heavy burden pneumonia continues to extract  
560 in the location necessitated this review of pneumococcal serotype epidemiology in Southeast Asia.

561 Based on our literature search and meta-analysis we found that the most common serogroups in IPD were 6  
562 (23.19%), 19 (22.99%) and 23 (16.03%) whilst the most frequent serotypes were 1 (39.87%), 3 (28.39%), and 4  
563 (21.09%). Notably, these results fit into the landscape of worldwide serotype prevalence in the pre-PCV era  
564 when serotypes 19F, 6B, 6A, and 23F were amongst the top ten most common serotypes observed in IPD, non-  
565 IPD and carriage in children <5 years of age (126, 127). These 10 serotypes were deemed to be responsible for  
566 >70% of IPDs globally, and 65-76% of paediatric carriage events in Europe and Asia prior to the introduction of  
567 PCVs. Our serogroup results are also in concordance with data reported in 2012, however the IPD causing  
568 serotypes have changed from 3, 34, and 1. Within serogroup 19, 19F was the most frequent which is especially  
569 worrying given its' high rates of resistance to penicillin, a first-line antibiotic for pneumococcal infections. In  
570 addition, some strains of serotype 19F may also be resistant to other antibiotics, such as macrolides and  
571 fluoroquinolone.<sup>128</sup> The use of conjugate vaccines can help prevent pneumococcal disease caused by antibiotic-  
572 resistant strains, and previous studies have proven their efficacy against serotype 19F in IPD (129 – 131).  
573 Within serogroup 6 and 23, the most frequently observed serotypes were 6B and 23F. Both are also included in  
574 all currently licenced and available PCVs. Moreover, all three most common IPD causing serotypes are also  
575 VTs - serotypes 1 and 4 are covered by PCV10 and above, and all three all included in PCV13 and other higher  
576 valent vaccines on the market. This demonstrates that ASEAN countries that are currently using PCV13 have  
577 likely achieved an adequate vaccine coverage and successfully mitigated pneumococcal diseases caused by  
578 these serotypes. However, it is important to note that these figures should be regarded as a conservative estimate  
579 due to differing levels of reporting accuracy and diagnosis between countries in ASEAN. Additionally, ongoing  
580 surveillance will be crucial, particularly for countries like Malaysia, which recently implemented PCV10 in their  
581 NIP. Monitoring will help assess the effectiveness of the vaccine and enable the adoption of a higher valency  
582 formulation if required.

583 The frequency of carried serotypes across countries and age groups slightly differed from those of IPD. Notably,  
584 the most carried serotype was 34, followed by serotypes 3 and 4. It is not uncommon to observe prevalent  
585 NVTs, such as 34, in countries where PCVs are not widely used or unavailable. For example, in 2015, the most  
586 common non-PCV13 isolates were serotype 34 in hospitalized children in Shanghai Children Hospital (132).  
587 This serotype is considered to have intermediate to high virulence i.e., capable of causing invasive diseases but  
588 less virulent than those of greater concern such as 1, 3, 7F, and 19A (133). Nevertheless, our data reveals an  
589 increase in IPDs caused by serotype 34, which ranked fourth among the most common serotypes (3.76%) in this  
590 disease group. This represents a rise compared to the 1% observed during the systematic review conducted in  
591 2012 (24). It is important to note that newly emerging NVTs like serotype 34 may result from serotype-

592 replacement after vaccination as was observed following the introduction of PCV7 in England (131). To date,  
593 serotype 34 is generally known to be susceptible to several antibiotics, including penicillin, amoxicillin, and  
594 some cephalosporins (134) however, resistance has been noted and therefore warrants continued vigilance (59,  
595 135).

596 The frequency of vaccine serotypes causing IPDs was the highest in Thailand, followed by Malaysia, Vietnam,  
597 Singapore, Philippines, Cambodia, Laos, Indonesia and Myanmar. Country-specific burdens however remain  
598 problematic to determine given the ongoing lack of data and this ranking should be viewed with caution. For  
599 example, the available data on IPD serotypes in Laos and Indonesia was limited and we were unable to locate  
600 any information on the prevalence of IPD in Myanmar. Contrastingly, in carriage Myanmar had the highest  
601 reported vaccine serotype prevalence, followed by Indonesia, Vietnam, Cambodia, Thailand, Malaysia, Laos,  
602 Philippines, and Singapore.

603 Most of the isolates (61.31%) in the ASEAN analysed in this study were from carriage. While asymptomatic  
604 colonization of pneumococci is common, individuals carrying highly virulent serotypes could be at risk of  
605 developing pneumococcal diseases. Therefore, the identification of serotypes carried in healthy individuals can  
606 help assess the circulating serotypes in the population and identify those that could potentially cause disease in  
607 vulnerable individuals and those who have not been vaccinated. Our study revealed that the predominant  
608 serotypes detected in carriage were consistent with those observed in IPDs. Specifically, serotypes 19F, 23F,  
609 and 6B were identified as the most common serotypes in both carriage and IPD. Therefore, pneumococcal  
610 carriage studies can aid us to predict the impact vaccines can make in preventing and assess impact.

611 Continued surveillance of pneumococcal serotypes is essential to track changes in their prevalence as vaccines  
612 are implemented. Countries such as Malaysia, which most recently have adopted PCV10, should pay close  
613 attention to ongoing surveillance of pneumococcal serotypes. This is particularly crucial since the vaccine  
614 formulation does not include other high-virulence serotypes such as 19A, which are known to cause IPD and  
615 was found the 2<sup>nd</sup> most common serotype within serogroup 19 in our analysis and also overall the 3<sup>rd</sup> most  
616 frequent serotype in Malaysia. With the increasing immunization of the population through PCV10, the number  
617 of vaccine serotypes in circulation is expected to decrease. Consequently, serotypes that are not covered by  
618 PCV10 may experience less competition and start to increase in prevalence. While PCV13 provides broader  
619 coverage of pneumococcal serotypes than PCV10, the latter includes protein D from non-typeable *Haemophilus*  
620 *influenzae* (NTHi) as a carrier for the vaccine's pneumococcal serotypes. This may offer a more comprehensive  
621 protection against the non-invasive disease acute otitis media (AOM), as shown in a study (136). Although  
622 Synflorix® (PCV10) does not include serotype 19A in its selection, it may still provide some degree of cross-  
623 protection against this serotype. However, studies investigating this are inconclusive (137).

624 NT pneumococci accounted for 10.42% [95%CI: 9.95 – 10.89] of total serotypes. NT pneumococci can cause  
625 clinical disease, particularly in neonates and young infants, and studies have demonstrated an increase in NT  
626 carriage following the implementation of PCV (138). Further, their potential role in the spread of antimicrobial  
627 resistance has been shown with NT pneumococci exhibiting higher rates of recombination of genes *in vitro*  
628 compared with capsulated pneumococci (139). This highlights the importance of further studies so that  
629 epidemiology and pathogenesis can be better understood.

630 Despite the known advantages of using PCV the main barriers to widespread immunisation in MICs need to be  
631 acknowledged. Insufficient data reporting and the absence of pneumococcal surveillance programs pose  
632 challenges in evaluating the public health requirements of the population and consequently developing  
633 evidence-based public health policies (21). However, epidemiological data is vital for informing vaccine policy  
634 (140) which cannot rely on a single review or cost-benefit analysis. Instead, it necessitates continuous and  
635 rigorous research to establish a comprehensive evidence base. Cross-border collaboration has been promoted as  
636 a critical health improvement strategy (141) therefore, the ASEAN network should aid each other in the  
637 development of policy. Pneumococcal surveillance programmes are needed to better understand the  
638 pneumococcal burden, as well as track progress on vaccination programmes and offers insight into herd  
639 immunity effects (142).

640 The most recent country to update their pneumococcal vaccination policy is Malaysia opting to introduce  
641 PCV10, which has been accessible through the NIP since December 2020. This decision is beneficial as it will  
642 aid in reducing pneumococcal disease and lowering antimicrobial resistance in the country. Malaysia has been  
643 shown to have resistant pneumococci and particularly high penicillin resistance (123) along with multi-drug  
644 resistant pneumococci which is comparable to other countries in Asia (68). The implementation of PCV10 in  
645 Malaysia underscores the need for comprehensive pneumococcal surveillance programs across the country. As  
646 we have previously emphasized (143) such programs are critical for evaluating vaccine efficacy and informing  
647 policy decisions.

648 One of the key strengths of this study was its thorough search process, which involved searching multiple  
649 databases without limiting the publication start date to ensure that all relevant studies from the pre-PCV era  
650 were included. Additionally, our study has taken into consideration the potential use of the newly licensed  
651 PCV15 and PCV20 vaccines to determine their theoretical coverage of various serotypes. However, this study  
652 has certain limitations. The reviewed studies often had small sample sizes, non-standardized sampling methods,  
653 and inadequate duration. Moreover, the studies were frequently conducted in a single location within a country,  
654 thereby failing to provide a precise representation of the epidemiology across the broader population. A few  
655 studies only reported serogroups without conducting additional serotyping, while others reported ‘unknown’  
656 serotypes. This makes it difficult to report increases in specific serotypes and fails to provide a comprehensive  
657 picture of serotype distribution. These findings also do not contribute meaningfully to the study calculations as it  
658 is unclear whether the serotypes are vaccine-types or not. Some studies included in this review did not account  
659 for antibiotic use or prior vaccination status of the participants, which would affect the serotypes observed.

660 This study focused on the serotype prevalence prior to the introduction of PCV vaccines, with the calculated  
661 vaccine coverages heavily reliant on the availability of data published during this time period. In order to gain a  
662 more accurate understanding of the actual vaccine coverage in the region, this study highlights the potential of  
663 conducting a comprehensive review and meta-analysis of the data published following the implementation of  
664 the vaccines.

665

666

667

668 **Conclusion**

669 This study shows it is imperative that ongoing surveillance of pneumococci in the ASEAN region be  
670 established, utilising comparable approaches to ensure high-quality studies that yield valuable insights into  
671 vaccine policy and program efficacy. Comprehensive research encompassing IPD, non-IPD, and pneumococcal  
672 carriage is necessary to monitor changes in serotype distribution, assess the impact of vaccination on circulating  
673 serotypes and strengthen vaccine policies. Such efforts will help safeguard public health measures ultimately  
674 reducing the burden of pneumococcal disease in the most affected parts of the world.

675 **List of Abbreviations**

676 ASEAN = Association of Southeast Asian Nations

677 IPD = Invasive Pneumococcal Disease

678 LMIC = Low and Middle-Income Countries

679 Non-IPD = Non-Invasive Pneumococcal Disease

680 NT = Non-Typeable

681 NVT = Non-Vaccine Type

682 PCV = Pneumococcal Conjugate Vaccine

683 VRT = Vaccine-Related Types

684 VT = Vaccine Type

685 **Ethics approval and consent to participate**

686 Not applicable.

687 **Consent for publication**

688 Not applicable.

689 **Availability of data and Materials**

690 All data generated or analysed during this study are included in this published article.

691 **Competing interests**

692 I have read the journal's policy and the authors of this manuscript have the following competing interests: SCC  
693 acts as principal investigator on studies conducted on behalf of University Hospital Southampton NHS  
694 Foundation Trust and the University of Southampton that are sponsored by vaccine manufacturers but receives  
695 no personal payments. SCC has received financial assistance from vaccine manufacturers to attend conferences.  
696 SCC has participated in advisory boards for vaccine manufacturers but receives no personal payments. DWC  
697 was a post-doctoral researcher on projects funded by Pfizer and GSK between April 2014 and 20th October  
698 2017. All other authors have no conflicts of interest.

699 **Authors contributions**

700 SCC planned the review. AJJL and ED wrote the initial draft and conducted the data analysis. DWC and SCC  
701 reviewed the draft manuscript and directed the edits. DWC and SCC reviewed the final draft and gave  
702 recommendations to additional research, structure and clarity. AJJL and ED made corrections and additions to  
703 the final draft and AJJL made the submission.

704 **Acknowledgements**

705 This work arose from a dissertation submitted by AJJL in partial fulfilment of the requirements for the Degree  
706 of Master of Science (Public Health) at the University of Southampton.

707 **Funding**

708 This study was funded, in part, by a Global Partnership Award to SCC from the University of Southampton via  
709 the World Universities Network and a Pfizer GMG grant ID#69396685 to SCC. The funders had no role in  
710 study design, data collection and analysis, decision to publish, or preparation of the manuscript.

711 **References**

1. Cleary DW, Clarke SC. The nasopharyngeal microbiome. *Emerging Topics in Life Sciences*. 2017; 1(4): 297-312.
2. Ndlangisa K, du Plessis M, Allam M, Wolter N, de Fouveia L, Klugman K, et al. Invasive disease caused simultaneously by dul serotypes of streptococcus pneumoniae. *Journal of Clinical Microbiology*. 2017; 56(1).
3. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. *The Lancet Infectious Diseases*. 2004; 4(3): 144 - 154.
4. Ghimire M, Bhattacharya S, Narain J. Pneumonia in South-East Asia Region: Public Health perspective. *The Indian Journal of Medical Research*. 2012; 135: 459 - 468.
5. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. *Journal of Global Health*. 2013; 3(1): 010401.
6. Global Pneumococcal Sequencing Project. Serotypes. [Online].; 2022. Cited 2023 03 02. Available from: <https://www.pneumogen.net/gps/serotypes.html>.
7. Papadatou I, Tzovara I, Licciardi PV. The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects. *Vaccines (Basel)*. 2019; 7(1): 13.
8. Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. *PLOS ONE*. 2017; 12(1): e0169368.

9. Westerink MAJ, Schroeder HW, Nahm MH. Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. *Aging and Disease*. 2011; 3(1): 51 - 67.
10. European Medicines Agency. Synflorix. [Online].; 2023. Cited 2023 05 16. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/synflorix>.
11. Berman-Rosa M, O'Donnell S, Barker M, Quach C. Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease. *Pediatrics*. 2020; 145(4): e20190377.
12. CDC. Pneumococcal Vaccination: Summary of Who and When to Vaccinate. [Online].; 2023. Cited 2023 05 03. Available from: <https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html>.
13. FDA. Vaxneuvance. [Online].; 2022. Cited 2022 07 10. Available from: <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance>.
14. Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. *Morbidity and Mortality Weekly Report*. 2022; 71(4): 109 - 117.
15. EMA. Vaxneuvance. [Online].; 2022. Cited 2023 03 02. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/vaxneuvance>.
16. Pfizer. European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults. [Online].; 2022. Cited 2022 07 10. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-approves-pfizers-20-valent#:~:text=On%20June%208%2C%202021%2C%20Pfizer,age%2018%20years%20or%20older>.
17. CDC. Pneumococcal Vaccination: What Everyone Should Know. [Online]. Cited 2023 02 27. Available from: <https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html>.
18. EMA. Apexxnar. [Online].; 2022. Cited 2023 03 02. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/apexxnar>.
19. Pharmaceutical Journal. MHRA approves first vaccine in ten years to protect children against pneumococcal diseases. *The Pharmaceutical Journal*. 2022; 309(7967): 7967.
20. Chapman R, Sutton K, Dillon-Murphy D, Patel S, Hilton B, Farkouh R, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis. *Vaccine*. 2020; 38(45): 7138 - 7145.
21. Tricarico S, McNeil HC, Head MG, Cleary DW, Clarke SC. Informing pneumococcal conjugate vaccine policy in middle income countries: The case of Malaysia. *Vaccine*. 2017; 18(35): 2288-2290.

22. UNICEF. Pneumonia. [Online].; 2022. Cited 2023 05 03. Available from: <https://data.unicef.org/topic/child-health/pneumonia/>.
23. Gamil A, Chokeyhabulkit K, Phongsamart W, Techasaensiri C, Pirilam B, Thamaree R. Pneumococcal disease in Thailand. *International Journal of Infectious Diseases*. 2021; 102(1): 429 - 436.
24. Jauneikaite E, Jefferies J, Hibberd M, Clarke SC. Prevalence of *Streptococcus pneumoniae* serotypes causing invasive and non-invasive disease in South East Asia: A review. *Vaccine*. 2012; 30(24): 3503 - 3514.
25. CASP. Systematic Review. [Online].; 2023. Cited 2023 02 14. Available from: <https://casp-uk.net/glossary/systematic-review/>.
26. JBI. Checklist for prevalence studies. [Online].; 2023. Cited 2023 02 14. Available from: [https://jbi.global/sites/default/files/2019-05/JBI\\_Critical\\_Appraisal-Checklist\\_for\\_Prevalence\\_Studies2017\\_0.pdf](https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Prevalence_Studies2017_0.pdf).
27. Turner P, Turner C, Jankhot A, Helen N, Lee SJ, Day NP, et al. A longitudinal study of *Streptococcus pneumoniae* carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. *PLOS ONE*. 2012; 7(5): e38271.
28. Turner P, Turner C, Suy K, Soeng S, Ly S, Miliya T. Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia. *Emerging Infectious Diseases*. 2015; 21(11): 2080 - 2083.
29. Moore C, Giess A, Soeng S, Sar P, Kumar V, Nhong P, et al. Characterisation of invasive streptococcus pneumoniae isolates from Cambodian children between 2007 - 2012. *PLOS ONE*. 2016; 11(7): e0159358.
30. Inghammar M, By Y, Farris C, Phe T, Borand L, Kerleguer A, et al. Serotype Distribution of Clinical *Streptococcus pneumoniae* Isolates before the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Cambodia. *The American Journal of Tropical Medicine and Hygiene*. 2018; 98(3): 791 - 796.
31. Dananché C, Paranhos-Baccalà G, Messaoudi M, Sylla M, Awasthi S, Bavdekar A, et al. Serotypes of *Streptococcus pneumoniae* in Children Aged >
32. Turner P, Leab P, Ly S, Sao S, Miliya T, Heffelfinger JD, et al. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Colonization and Invasive Disease in Cambodian Children. *Clinical Infectious Diseases*. 2020; 70(8): 1580 - 1588.
33. Farida H, Severin JA, Gasem MH, Keuter M, Wahyono H, van den Broek P, et al. Nasopharyngeal Carriage of *Streptococcus pneumoniae* in Pneumonia-Prone Age Groups in Semarang, Java Island, Indonesia. *PLOS ONE*. 2014; 9(1): e87431.



34. Hadinegoro SR, Prayitno A, Khoeri MM, Djelantik IGG, Dewi NE, Indriyani SAK, et al. Nasopharyngeal carriage of streptococcus pneumoniae in healthy children under five years old in central Lombok regency, Indonesia. *The Southeast Asian journal of tropical medicine and public health*. 2016; 47(3): 485 - 493.
35. Harimurti K, Saldi SRF, Dewiasty E, Khoeri MM, Yuniastuti E, Putri T, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in adults infected with human immunodeficiency virus in Jakarta, Indonesia. *Journal of Infection and Public Health*. 2016; 9(5): 633 - 638.
36. Dunne EM, Murad C, Sudigdoadi S, Fadlyana E, Tarigan R, Indriyani SAK, et al. Carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Indonesian children: A cross-sectional study. *PLOS ONE*. 2018; 13(4): e0195098.
37. Safari D, Kurniati N, Waslia L, Khoeri MM, Putri T, Bogaert D, et al. Serotype Distribution and Antibiotic Susceptibility of Streptococcus pneumoniae Strains Carried by Children Infected with Human Immunodeficiency Virus. *PLOS ONE*. 2014; 9(10): e110526.
38. Safari D, Mudaliana S, Harimurti K, Waslia L, Subekti D. Nasopharyngeal colonization of streptococcus pneumoniae in elderly people in Jakarta Indonesia. *International Journal of Infectious Diseases*. 2012; 16(1): E313.
39. Soewignjo S, Gessner BD, Sutanto A, Steinhoff M, Prijanto M, Nelson C, et al. Streptococcus pneumoniae nasopharyngeal carriage prevalence, serotype distribution, and resistance patterns among children on Lombok Island, Indonesia. *Clinical Infectious Diseases*. 2001; 32(7): 1039 - 43.
40. Said WF, Sukoto E, Khoeri MM, Kumalawati J, Safari D. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from adult patients in Jakarta, Indonesia. *Journal of Infection and Public Health*. 2017; 10(6): 833 - 835.
41. Yulianti K, Hadinegoro SR, Supriyatno B, Karuniawati A. Invasive pneumococcal disease among hospitalized children aged 28 days to 60 months in Jarkarta. *Southrast Asian Journal of Tropical Medicine and Public Health*. 2012; 43(1): 136 - 144.
42. Amanda G, Tafroji W, Sutoyo DK, Burhan E, Haryanto B, Safari D. Serotype distribution and antimicrobial profile of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Jakarta, Indonesia. *Journal of Microbiology, Immunology and Infection*. 2021; 54(6): 1175 - 1178.
43. Murad C, Dunne EM, Sudigdoadi S, Fadlyana E, Tarigan R, Pell CL, et al. Pneumococcal carriage, density, and co-colonization dynamics: A longitudinal study in Indonesian infants. *International Journal of Infectious Diseases*. 2019; 86: 73 - 81.

44. Purwanto DS, Loho T, Tafroji W, Mangunatmadja I, Immanuel S, Timan IS, et al. Isolation and identification of *Streptococcus pneumoniae* serotype 6B from a patient with bacterial meningitis infection in Jakarta, Indonesia. *Access Microbiology*. 2020; 2(5).
45. Safari D, Mudaliana S, Harumurti K, Waslia L, Subekti D. *Staphylococcus aureus* and *Streptococcus pneumoniae* prevalence among elderly adults in Jakarta, Indonesia. *Southeast Asian Journal of Tropical Medicine and Public Health*. 2012; 16(1): e313.
46. Safari D, Valentiya F, Salsabila K, Paramaiswari WT, Tafroji W, Hammerschmidt S, et al. The prevalence of pilus islets in *Streptococcus pneumoniae* isolates from healthy children in Indonesia. *Access Microbiology*. 2021; 3(1): acmi000184.
47. Wahyono DJ, Khoeri MM, Darmawan AB, Wijayanti SPM, Mumpuni A, Nawangtantri G, et al. Nasopharyngeal carriage rates and serotype distribution of *Streptococcus pneumoniae* among school children with acute otitis media in Central Java, Indonesia. *Access Microbiology*. 2021; 3(7): 000249.
48. Salsabila K, Paramaiswari WT, Amalia H, Ruyani A, Tafroji W, Winarti Y, et al. Nasopharyngeal carriage rate, serotype distribution, and antimicrobial susceptibility profile of *Streptococcus pneumoniae* isolated from children under five years old in Kotabaru, South Kalimantan, Indonesia. *Journal of Microbiology, Immunology and Infection*. 2022; 55(3): 482 - 488.
49. Harimurti K, Saldi SRF, Dewiasty E, Alfarizi T, Dharmayuli M, Khoeri MM, et al. *Streptococcus pneumoniae* carriage and antibiotic susceptibility among Indonesian pilgrims during the Hajj pilgrimage in 2015. *PLoS One*. 2021; 16(1): e0246122.
50. Muktiari D, Khoeri MM, Tafroji W, Waslia L, Safari D. Serotypes and antibiotic susceptibility profile of *Streptococcus pneumoniae* isolated from nasopharynges of children infected with HIV in Jakarta, Indonesia, pre- and post-pneumococcal vaccination. *Access Microbiology*. 2021; 3(3): 000215.
51. Prayitno A, Supriyatno B, Munasir Z, Karuniawati A, Hadinegoro SRS, Prihartono J, et al. Pneumococcal nasopharyngeal carriage in Indonesia infants and toddlers post-PCV13 vaccination in a 2+1 schedule: A prospective cohort study. *PLoS ONE*. 2021; 16(1): e0245789.
52. Safari D, Widhidewi NW, Paramaiswari WT, Lila Paramasatiari AAA, Maharani Putri HF, A Asih Ratnadi IG, et al. Prevalence, Serotype Distribution, and Antimicrobial Susceptibility Profile of *Streptococcus pneumoniae* among Patients with Acute Respiratory Tract Infection. *WHO South-East Asia Journal of Public Health*. 2021; 10(2): 66 - 69.
53. Moore CE, Sengduangphachanh A, Thaojaikon T, Sirisouk J, Foster D, Phetsouvanh R, et al. Enhanced determination of *Streptococcus pneumoniae* serotypes associated with invasive disease in Laos by using a real-time polymerase chain reaction serotyping assay with cerebrospinal fluid. *American Society of Tropical Medicine and Hygiene*. 2010; 83(3): 451 - 457.

54. Satzke C, Dunne EM, Choummanivong M, Ortika BD, Neal EFG, Pell CL, et al. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine. *Vaccine*. 2019; 37(2): 296 - 305.
55. Cheong YM, Jegathesan M, Henrichsen J, Wong YH, Ng AJ, Louis A. Antibiotic susceptibility and serotype distribution of *Streptococcus pneumoniae* in Malaysian children. *Journal of Tropical Pediatrics*. 1988; 34(4): 182 - 185.
56. Shakrin N, Masri S, Taib N, Nordin S, Jamal F, Desa M. Genotypic characterization of Malaysian human isolates of *Streptococcus pneumoniae* from carriage and clinical sources. *Comparative Immunology, Microbiology and Infectious Disease*. 2014; 37(5-6): 347-354.
57. Rohani M, Raudzah A, Ng A, Ng P, Zaidatul A, Asmah I, et al. Epidemiology of *Streptococcus pneumoniae* infection in Malaysia. *Epidemiology and Infection*. 1999; 122(1): 77-82.
58. Desa M, Lin T, Yasin R, Parasakthi N. Penicillin susceptibility and molecular characteristics of clinical isolates of *Streptococcus pneumoniae* at the University of Malaya Medical Center, Kuala Lumpur, Malaysia. *International Journal of Infectious Diseases*. 2003; 7(3): 190-197.
59. Le C, Palanisamy N, Mohd Yusof M, Sekaran S. Capsular serotype and antibiotic resistance of streptococcus pneumoniae isolates in Malaysia. *PLOS ONE*. 2011; 6(5): e19547.
60. Jefferies J, Mohd Yusof M, Devi Sekaran S, Clarke S. Novel Clones of *Streptococcus pneumoniae* causing invasive disease in Malaysia. *PLOS ONE*. 2014; 9(6): e97912.
61. Rohani M, Zin N, Hussin A, Nawi S, Hanapiah S, Wahab Z, et al. Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals. *Vaccine*. 2011; 29(34): 5688-5693.
62. Yatim M, Masri S, Desa M, Taib N, Nordin S, Jamal F. Determination of phenotypes and pneumococcal surface protein A family types of *Streptococcus pneumoniae* from Malaysian healthy children. *Journal of Microbiology, Immunology and Infection*. 2013; 46(3): 180-186.
63. Subramaniam P, Jabar K, Kee B, Chong C, Nathan A, de Bruyne J, et al. Serotypes & penicillin susceptibility of *Streptococcus pneumoniae* isolated from children admitted to a tertiary teaching hospital in Malaysia. *Indian Journal of Medical Research*. 2018; 148(2): 225.
64. Goh SL, Kee BP, Jabar KA, Chua KH, Nathan AM, Bruyne J, et al. Molecular detection and genotypic characterisation of *Streptococcus pneumoniae* isolated from children in Malaysia. *Pathogens and Global Health*. 2020; 114(1): 46 - 54.

65. Arushothy R, Ahmad N, Amran F, Hashim R, Samsudin N, Rosalina Che Azih C. Pneumococcal serotype distribution and antibiotic susceptibility in Malaysia: A four-year study (2014-2017) on invasive paediatric isolates. *International Journal of Infectious Diseases*. 2019; 80: 129-133.
66. Bahtar A, Abdul Manap R, Ban A. A study of the prevalence of streptococcus pneumoniae serotypes in patients hospitalised for community-acquired pneumonia. *European Respiratory Journal*. 2016; 48.
67. Cleary DW, Morris DE, Anderson RA, Jones RA, Alattraqchi AG, Rahman NI, et al. The upper respiratory tract microbiome of indigenous Orang Asli in north-eastern Peninsular Malaysia. *NPJ Biofilms and Microbiomes*. 2021; 7(1).
68. Dzaraly ND, Desa MNM, Muthanna A, Masri SN, Taib NM, Suhaili Z, et al. Antimicrobial susceptibility, serotype distribution, virulence profile and molecular typing of piliated clinical isolates of pneumococci from east coast, Peninsular Malaysia. *Scientific Reports*. 2021; 11(8220).
69. Morris DE, McNeil H, Hocknell RE, Anderson , Tuck AC, Tricarico S, et al. Carriage of upper respiratory tract pathogens in rural communities of Sarawak, Malaysian Borneo. *Pneumonia*. 2021; 13(6).
70. Ngoi ST, Muhamad AN, Teh CSJ, Chong CW, Jabar KA, Chai LC, et al.  $\beta$ -Lactam Resistance in Upper Respiratory Tract Pathogens Isolated from a Tertiary Hospital in Malaysia. *Pathogens*. 2021; 10(12): 1602.
71. Yusof HA, Desa MNM, Masri SN, Malina O, Jamal F. Hyaluronatylase production by *Streptococcus pneumoniae* isolated from patients and carriers. *Tropical Biomedicine*. 2015; 32(3): 413 - 418.
72. Htoon TT, Oo NAT, Aung WW, Thu HM, Mon M, Yamaguchi M, et al. Serotype Distribution and Antimicrobial Susceptibility Profile of *Streptococcus pneumoniae* Among Myanmar Children with Acute Respiratory Infection. *International Journal of Bacteriology & Parasitology*. 2018; 2018(1).
73. Turner P, Melchiorre S, Moschioni M, Barocchi MA, Turner C, Watthanaworawit W, et al. Assessment of *Streptococcus pneumoniae* pilus islet-1 prevalence in carried and transmitted isolates from mother–infant pairs on the Thailand–Burma border. *Clinical Microbiology and Infection*. 2012; 18(10): 970 - 975.
74. Turner P, Hinds J, Turner C, Jankhot A, Gould K, Bentley SD, et al. Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. *Journal of Clinical Microbiology*. 2011; 49(5): 1784 - 1789.
75. Turner P, Turner C, Jankhot A, Phakaudom K, Nosten F, Goldblatt D. Field Evaluation of Culture plus Latex Sweep Serotyping for Detection of Multiple Pneumococcal Serotype Colonisation in Infants and Young Children. *PLoS One*. 2013; 8(7).

76. Yamaguchi M, Win HPM, Higashi K, Ono M, Hirose Y, Motooka D, et al. Epidemiological analysis of pneumococcal strains isolated at Yangon Children's Hospital in Myanmar via whole-genome sequencing-based methods. *Microbial Genomics*. 2021; 7(2): 000523.
77. Capeding MR, Sombrero LT, Lucero MG, Saniel MC. Serotype distribution and antimicrobial resistance of invasive *Streptococcus pneumoniae* isolates in Filipino children. *Journal of Infectious Diseases*. 1994; 169(2): 479 - 480.
78. Capeding MR, Bravo L, Santos J, Kilgore PE, Kim SA, Balter I, et al. Prospective surveillance study of invasive pneumococcal disease among urban children in the Philippines. *The Pediatric Infectious Disease Journal*. 2013; 32(10): e383 - 389.
79. Lupisan SP, Herva E, Sombrero LT, Quiambao BP, Capeding MRZ, Abucejo PE, et al. Invasive bacterial infections of children in a rural province in the central Philippines. *The American Journal of Tropical Medicine and Hygiene*. 2000; 62(3): 341 - 346.
80. Sombrero L, Nissinen A, Esparar G, Lindgren M, Siira L, Virolainen A&ObotAc. Low incidence of antibiotic resistance among invasive and nasopharyngeal isolates of *Streptococcus pneumoniae* from children in rural Philippines between 1994 and 2000. *European Journal of Clinical Microbiology & Infectious Diseases*. 2008; 27(10).
81. Sia SB, Lagrada ML, Gayeta JM, Masim MAL, Abad JP, Magbanua MA, et al. Serotype distribution and antimicrobial resistance of *Streptococcus pneumoniae* in the Philippines, 2012–2018. *Western Pacific Surveillance and Response Journal*. 2021; 12(4): 1-8.
82. Wright MS, McCorrison J, Gomez AM, Beck E, Harkins D, Shankar J, et al. Strain Level *Streptococcus* Colonization Patterns during the First Year of Life. *Frontiers in Microbiology*. 2017; 8: 1661.
83. Chong CY, Koh-Cheng T, Yee-Hui M, Nancy TWS. Invasive pneumococcal disease in Singapore children. *Vaccine*. 2008; 26(27-28): 3427 - 3431.
84. Hsu LY, Lui SW, Lee JL, Hedzlyn HMM, Kong DHL, Shameen S, et al. Adult invasive pneumococcal disease pre- and peri-pneumococcal conjugate vaccine introduction in a tertiary hospital in Singapore. *Journal of Medical Microbiology*. 2009; 58(1): 101 - 104.
85. Jauneikaite E, Jefferies JMC, Churton NWV, Lin RTP, Hibberd ML, Clarke SC. Genetic diversity of *Streptococcus pneumoniae* causing meningitis and sepsis in Singapore during the first year of PCV7 implementation. *Emerging Microbes and Infections*. 2014; 3(6): e39.
86. Jefferies JMC, Tee WSN, Clarke SC. Molecular analysis of *Streptococcus pneumoniae* clones causing invasive disease in children in Singapore. *Journal of Medical Microbiology*. 2011; 60(6).

87. Soh SWL, Poh CL, Lin RVTP. Serotype Distribution and Antimicrobial Resistance of *Streptococcus pneumoniae* Isolates from Pediatric Patients in Singapore. *Antimicrobial Agents and Chemotherapy*. 2000; 44(8): 2193 - 2196.
88. Thoon KC, Chong CY, Tee NWS. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010. *International Journal of Infectious Disease*. 2012; 16(3): e209 - e215.
89. Vasoo S, Singh K, Hsu LY, Chiew YF, Chow C, Lin RTP, et al. Increasing antibiotic resistance in *Streptococcus pneumoniae* colonizing children attending day-care centres in Singapore. *Respirology*. 2011; 16(8): 1241 - 1248.
90. Martinez-Vega R, Jauneikaite E, Thoon KC, Chua HY, Chua AH, Khong WX, et al. Risk factor profiles and clinical outcomes for children and adults with pneumococcal infections in Singapore: A need to expand vaccination policy? *PLoS ONE*. 2019; 14(10): e0220951.
91. Dejsirilert S, Overweg K, Sluijter M, Saengsuk L, Gratten M, Ezaki T, et al. Nasopharyngeal carriage of penicillin-resistant *Streptococcus pneumoniae* among children with acute respiratory tract infections in Thailand: a molecular epidemiological survey. *Journal of Clinical Microbiology*. 1999; 37(6): 1832 - 1838.
92. Levine S, Dejsirilert S, Sangsuk L, Chantra S, Feikin DR, Dowell SF, et al. Serotypes and antimicrobial resistance of *Streptococcus pneumoniae* in Thailand 2002-2004. *The Pediatric Infectious Disease Journal*. 2006; 25(2): 176 - 178.
93. Salter SJ, Turner C, Watthanaworawit W, de Goffau MC, Wagner J, Parkhill J, et al. A longitudinal study of the infant nasopharyngeal microbiota: The effects of age, illness and antibiotic use in a cohort of South East Asian children. *PLOS NEGLECTED TROPICAL DISEASES*. 2017; 11(10): e0005975.
94. Lochindarat S, Teeratakulpisarn J, Warachit B, Chanta C, Thapa K, Gilbert GL, et al. Bacterial etiology of empyema thoracis and parapneumonic pleural effusion in Thai children aged less than 16 years. *The Southeast Asian Journal of Tropical Medicine and Public Health*. 2014; 45(2): 442 - 454.
95. Phongsamart W, Srifeungfung S, Dejsirilert S, Chatsuwat T, Nunthapisud P, Treerathaweeraphong V, et al. Serotype distribution and antimicrobial susceptibility of *S. pneumoniae* causing invasive disease in Thai children younger than 5 years old, 2000–2005. *Vaccine*. 2007; 25(7): 1275 - 1280.
96. Phongsamart W, Srifeungfung S, Chatsuwat T, Nunthapisud P, Treerathaweeraphong V, Rungnobbakhun P, et al. Changing trends in serotype distribution and antimicrobial susceptibility of *Streptococcus pneumoniae* causing invasive diseases in Central Thailand, 2009–2012. *Human Vaccines & Immunotherapeutics*. 2014; 10(7): 1866 - 1873.

97. Rhodes J, Dejsirilert S, Maloney SA, Jorakate P, Kaewpan A, Salika P, et al. Pneumococcal Bacteremia Requiring Hospitalization in Rural Thailand: An Update on Incidence, Clinical Characteristics, Serotype Distribution, and Antimicrobial Susceptibility, 2005-2010. *PLOS ONE*. 2013; 8(6): e66038.
98. Srifeungfung S, Chokeyhaibulkit K, Tribuddharat C. Serotypes and antimicrobial susceptibilities of *Streptococcus pneumoniae* isolated from hospitalized patients in Thailand. *The Southeast Asian Journal of Tropical Medicine and Public Health*. 2007; 38(3): 469 - 477.
99. Srifeungfung S, Tribuddharat C, Comerungsee S, Chatsuwan T, Treerauthanaweeraphong V, Rungnobbhakhun P, et al. Serotype coverage of pneumococcal conjugate vaccine and drug susceptibility of *Streptococcus pneumoniae* isolated from invasive or non-invasive diseases in central Thailand, 2006–2009. *Vaccine*. 2010; 28(19): 3440 - 3444.
100. Srifeungfung S, Phongsamart W, Tribuddharat C, Chatsuwan T, Rungnobbhakhun P, Sapcharoen S, et al. Serotype distribution and antibiotic susceptibility of invasive *Streptococcus pneumoniae* isolates in patients aged 50 years or older in Thailand. *Human Vaccines & Immunotherapeutics*. 2014; 10(1): 40 - 44.
101. Wangirapan A, Ayuthaya SIN, Katip W, Kasatpibal N, Mektrirat R, Anukool U, et al. Serotypes and Vaccine Coverage of *Streptococcus Pneumoniae* Colonization in the Nasopharynx of Thai Children in Congested Areas in Chiang Mai. *Pathogens*. 2020; 9(12): 988.
102. Baggett HC, Peruski LF, Olsen SJ, Thamthitwat S, Rhodes J, Dejsirilert S, et al. Incidence of Pneumococcal Bacteremia Requiring Hospitalization in Rural Thailand. *Clinical Infectious Diseases*. 2009; 48(2): S65 - S74.
103. Suphanklang J, Santimaleeworagun W, Thunyaharn S, Traipattanakul J. Pneumococcal meningitis at a Thai hospital over a 10-year period: clinical outcomes, serotypes, and antimicrobial susceptibility patterns. *The Southeast Asian Journal of Tropical Medicine and Public Health*. 2017; 48(6): 1281 - 1289.
104. Suwanpakdee D, Samakoses R, Sirinavin S, Kerdpanich A, Simasathien S, Thunyaharn S, et al. Invasive pneumococcal disease in Phramongkutklao Hospital 2004-2008: clinical data, serotype distribution and antimicrobial resistance patterns. *Journal of the Medical Association of Thailand*. 2010; 93(5): S40 - 50.
105. Watanabe H, Asoh N, Hoshino K, Watanabe K, Oishi K, Kositsakulchai W, et al. Antimicrobial susceptibility and serotype distribution of *Streptococcus pneumoniae* and molecular characterization of multidrug-resistant serotype 19F, 6B, and 23F *Pneumococci* in northern Thailand. *Journal of Clinical Microbiology*. 2003; 41(9): 4178 - 4183.
106. Piralam B, Prospero C, Thamthitwat S, Bunthi C, Sawatwong P, Sangwichian O, et al. Pneumococcal colonization prevalence and density among Thai children with severe pneumonia and community controls. *PLOS ONE*. 2020; 15(4): e0232151.

107. Chongtrakool P, Aphiyakul Y, Choochur P, Pummangura C, Srifuengfung M, So-Ngern A, et al. Prevalence and Antimicrobial Susceptibility of *Streptococcus pneumoniae* Isolated from Hospital in Thailand between 2016 and 2020. *JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND*. 2022; 105(2): 113 - 120.
108. Phongsamart W, Srifeungfung S, Chatsuwat T, Rungnobbhakhun P, Maleesatharn A, Chokeyhaibulkit K. *Streptococcus pneumoniae* Causing Invasive Diseases in Children and Adults in Central Thailand, 2012–2016. *Vaccines (Basel)*. 2022; 10(8): 1368.
109. Bogaert D, Ha NT, Sluijter M, Lemmens N, De Groot R, Hermans PWM. Molecular epidemiology of pneumococcal carriage among children with upper respiratory tract infections in Hanoi, Vietnam. *Journal of Clinical Microbiology*. 2002; 40(11): 3903 - 3908.
110. Dhoubhadel BG, Yasunami M, Nguyen HAT, Suzuki M, Vu TH, Nguyen ATT, et al. Bacterial Load of Pneumococcal Serotypes Correlates with Their Prevalence and Multiple Serotypes Is Associated with Acute Respiratory Infections among Children Less Than 5 Years of Age. *PLOS ONE*. 2014; 9(10): e110777.
111. Parry CM, Diep TS, Wain J, Hoa NTT, Gainsborough M, Nga D, et al. Nasal Carriage in Vietnamese Children of *Streptococcus pneumoniae* Resistant to Multiple Antimicrobial Agents. *Antimicrobial Agents and Chemotherapy*. 2000; 44(3): 484 - 488.
112. Nguyen HAT, Fujii H, Vu HTT, Parry CM, Dang AD, Ariyoshi K, et al. An alarmingly high nasal carriage rate of *Streptococcus pneumoniae* serotype 19F non-susceptible to multiple beta-lactam antimicrobials among Vietnamese children. *BMC Infectious Diseases*. 2019; 19(1).
113. Schultz C, Vien LM, Campbell JI, Chau NVV, Diep TS, Hoang NVM, et al. Changes in the nasal carriage of drug-resistant *Streptococcus pneumoniae* in urban and rural Vietnamese schoolchildren. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2007; 101: 484 - 492.
114. Vu HTT, Yoshida LM, Suzuki M, Nguyen HAT, Nguyen CDL, Nguyen ATT, et al. Association Between Nasopharyngeal Load of *Streptococcus pneumoniae*, Viral Coinfection, and Radiologically Confirmed Pneumonia in Vietnamese Children. *The Pediatric Infectious Disease Journal*. 2011; 30(1): 11 - 18.
115. Watanabe K, Anh DD, Huong PLT, Nguyet NT, Anh NTH, Thi NT, et al. Drug-resistant pneumococci in children with acute lower respiratory infections in Vietnam. *Pediatrics International*. 2008; 50: 514 - 518.
116. Parry CM, Duong NM, Zhou J, Main NTH, Diep TS, Thinh LQ, et al. Emergence in Vietnam of *Streptococcus pneumoniae* Resistant to Multiple Antimicrobial Agents as a Result of Dissemination of the Multiresistant Spain23F-1 Clone. *Antimicrobial Agents and Chemotherapy*. 2002; 46(11): 3512 - 3517.



117. Higgins RA, Temple B, Dai VTT, Phan TV, Toan NT, Spry L, et al. Immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to vietnamese children at 18 months of age. *The Lancet Regional Health - Western Pacific*. 2021; 16: 100273.
118. Mohamed YH, Toizumi M, Uematsu M, Nguyen HAT, Le LT, Takegata M, et al. Prevalence of *Streptococcus pneumoniae* in conjunctival flora and association with nasopharyngeal carriage among children in a Vietnamese community. *Scientific Reports*. 2021; 11(1): 337.
119. Son BA, Hai TX, Cuong TV, Chinh DD, Le THH, Dung NM, et al. Serotype distribution and antibiotic resistance of *Streptococcus pneumoniae* isolates collected from unvaccinated children with pneumonia at a province in central Vietnam. *Iranian Journal of Microbiology*. 2022; 14(5): 653 - 661.
120. Toizumi M, Satoh C, Quilty BJ, Nguyen HAT, Madaniyazi L, Le LT, et al. Effect of pneumococcal conjugate vaccine on prevalence of otitis media with effusion among children in Vietnam. *Vaccine*. 2022; 40(36): 5366 - 5375.
121. Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, Fu Y, et al. Spread of drug-resistant *Streptococcus pneumoniae* in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. *Clinical Infectious Diseases*. 1999; 28(6): 1206 - 1211.
122. Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, et al. Changing trends in antimicrobial resistance and serotypes of *Streptococcus pneumoniae* isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. *Antimicrobial Agents and Chemotherapy*. 2012; 56(3): 1418-26.
123. Song J, Jung S, Ko KS, Kim NY, Son JS, Chang H, et al. High Prevalence of Antimicrobial Resistance among Clinical *Streptococcus pneumoniae* Isolates in Asia (an ANSORP Study). *Antimicrobial Agents and Chemotherapy*. 2004; 48(6): 2101 - 2107.
124. Lee NY, Song JH, Kim S, Peck KR, Ahn KM, Lee SI, et al. Carriage of Antibiotic-Resistant Pneumococci among Asian Children: A Multinational Surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). *Clinical Infectious Diseases*. 2001; 32(10): 1463 - 1469.
125. Kim S, Chung D, Song J, Baek J, Thamlikitkul V, Wang H, et al. Changes in serotype distribution and antimicrobial resistance of *Streptococcus pneumoniae* isolates from adult patients in Asia: Emergence of drug resistance non-vaccine serotypes. *Vaccine*. 2020; 38(38): 6065-6073.
126. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Hance LF, Reithinger R, et al. Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. *PLoS Medicine*. 2010; 7(10): e1000348.

127. Clifford S, Knoll MD, O'Brien KL, Pollington TM, Moodley R, Prieto-Merino D, et al. Global landscape of *Streptococcus pneumoniae* serotypes colonising healthy individuals worldwide before vaccine introduction; a systematic review and meta-analysis. *MedRxiv*. 2023.
128. Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. *Vaccine*. 2012; 30(17): 2728 - 2737.
129. Lo S, Gladstone RA, van Tonder AJ, Lees JA, du Plessis M, Benisty R, et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. *The Lancet Infectious Diseases*. 2019; 19(7): 759 - 769.
130. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine. *The New England Journal of Medicine*. 2003; 348: 1737 - 1746.
131. Flasche S, Jan Van Hoek A, Sheasby E, Waight P, Andrews N, Sheppard C, et al. Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study. *PLoS Medicine*. 2011; 8(4): e1001017.
132. Zhao W, Pan F, Wang B, Wang C, Sun Y, Zhang T, et al. Epidemiology Characteristics of *Streptococcus pneumoniae* From Children With Pneumonia in Shanghai: A Retrospective Study. *Frontiers in Cellular and Infection Microbiology*. 2019; 9.
133. Brueggemann AB, Peto TEA, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and Geographic Stability of the Serogroup-Specific Invasive Disease Potential of *Streptococcus pneumoniae* in Children. *The Journal of Infectious Diseases*. 2004; 190(7): 1203-1211.
134. Yoon JG, Jang AY, Kim MJ, Seo YB, Lee J, Choi YH, et al. Persistent serotype 3 and 19A invasive pneumococcal diseases in adults in vaccine era: Serotype-dependent difference in ceftriaxone susceptibility. *Vaccine*. 2022; 40(15): 2258 - 2265.
135. Kandasamy r, Lo S, Gurung M, Carter MJ, Gladstone R, Lees J, et al. Effect of childhood vaccination and antibiotic use on pneumococcal populations and genome-wide associations with disease among children in Nepal: an observational study. *The Lancet Microbe*. 2022; 3(7): e503 - e511.
136. Rahman T, de Gier C, Orami T, Seppanen EJ, Granland CM, Francis JP, et al. PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life. *Vaccine*. 2021; 39(26): 3486 - 3492.
137. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? *BMC Pediatrics*. 2010; 10.

138. Chen HH, Hsu MH, Wu TL, Li HC, Chen CL, Janapatla RP, et al. Non-typeable *Streptococcus pneumoniae* infection in a medical center in Taiwan after wide use of pneumococcal conjugate vaccine. *Journal of Microbiology, Immunology and Infection*. 2020; 53(1): 94 - 98.
139. Marks LR, Reddinger RM, Hakansson AP. High Levels of Genetic Recombination during Nasopharyngeal Carriage and Biofilm Formation in *Streptococcus pneumoniae*. *mBio*. 2012; 3(5): e00200 - e00212.
140. Richardson A, Morris DE, Clarke SC. Vaccination in Southeast Asia—Reducing meningitis, sepsis and pneumonia with new and existing vaccines. *Vaccine*. 2014; 32(33): 4119 - 4123.
141. Lee KS, Ming LC, Lean QY, Yee SM, Patel R, Taha NA, et al. Cross-border Collaboration to Improve Access to Medicine: Association of Southeast Asian Nations Perspective. *Journal of Epidemiology and Global Health*. 2019; 9(2): 93 - 97.
142. Coughtrie AL, Jefferies JM, Cleary D, Doncaster CP, Faust S, Kraaijeveld A, et al. Microbial epidemiology and carriage studies for the evaluation of vaccines. *Journal of Medical Microbiology*. 2019; 68(10).
143. Lister AJJ, Le CF, Cheah ESG, Desa MNM, Cleary DW, Clarke SC. Serotype distribution of invasive, non-invasive and carried *Streptococcus pneumoniae* in Malaysia: a meta-analysis. *Pneumonia*. 2021; 13(9).




Figure 1 PRISMA





Figure 2





Figure 13





Figure 14





Figure 15







Figure 16





Figure 17





Figure 18





Figure 19





Figure 20





Figure 21





Figure 22





Figure 23







Figure 24





Figure 25





Figure 26





Figure 27





Figure 28





Figure 29





Figure 30





Figure 31







Figure 32





Figure 33





Figure 34





Figure 35





Figure 36





Figure 3





Figure 4





Figure 5







Figure 6





Figure 7





Figure 8





Figure 9





Figure 10





Figure 11





Figure 12